These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 1707553)

  • 1. Patient attitudes toward testing for maternal serum alpha-fetoprotein values when results are false-positive or true-negative.
    Earley KJ; Blanco JD; Prien S; Willis D
    South Med J; 1991 Apr; 84(4):439-42. PubMed ID: 1707553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The psychological impact of false positive elevations of maternal serum alpha-fetoprotein.
    Burton BK; Dillard RG; Clark EN
    Am J Obstet Gynecol; 1985 Jan; 151(1):77-82. PubMed ID: 2578251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Informed consent for maternal serum alpha-fetoprotein screening in an inner city population: how informed is it?
    Freda MC; DeVore N; Valentine-Adams N; Bombard A; Merkatz IR
    J Obstet Gynecol Neonatal Nurs; 1998; 27(1):99-106. PubMed ID: 9475134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated maternal serum alpha-fetoprotein values. How low is high?
    Lenke RR; Guerrieri J; Nemes JM; Kurczynski TW; French B; Gray M; Schut H; Ashwood ER
    J Reprod Med; 1989 Aug; 34(8):511-6. PubMed ID: 2478705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results and benefits of a maternal serum alpha-fetoprotein screening program.
    Milunsky A; Alpert E
    JAMA; 1984 Sep; 252(11):1438-42. PubMed ID: 6206249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The choices women make about prenatal diagnosis.
    Evans MI; Pryde PG; Evans WJ; Johnson MP
    Fetal Diagn Ther; 1993 Apr; 8(Suppl. 1):70-80. PubMed ID: 11653025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The significance of abnormally high and low maternal serum alpha-fetoprotein levels between 14 and 25 weeks of gestation.
    Ko TM; Hsieh FJ; Wu CC; Chang CH; Hsieh RF; Liu IJ; Hsieh CY; Lee TY
    J Formos Med Assoc; 1990 Jun; 89(6):456-60. PubMed ID: 1700059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What participants understand about a maternal serum alpha-fetoprotein screening program.
    Faden RR; Chwalow AJ; Orel-Crosby E; Holtzman NA; Chase GA; Leonard CO
    Am J Public Health; 1985 Dec; 75(12):1381-4. PubMed ID: 2415009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pregnant women's attitudes and knowledge in relation to access to serum-alpha-fetoprotein test.
    Sandén ML; Bjurulf P
    Scand J Soc Med; 1988; 16(4):197-204. PubMed ID: 2466330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abnormal maternal serum alpha fetoprotein and pregnancy outcome.
    Zarzour SJ; Gabert HA; Diket AL; St Amant M; Miller JM
    J Matern Fetal Med; 1998; 7(6):304-7. PubMed ID: 9848697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of provider characteristics and insurance status on maternal serum alpha-fetoprotein screening.
    Jenkins-Woelk LD; Baldwin LM; Raine TR; Hart LG; Fordyce MA; Rosenblatt RA
    J Am Board Fam Pract; 1998; 11(5):357-65. PubMed ID: 9796765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between second trimester maternal serum alpha-fetoprotein and umbilical artery Doppler velocimetry and their association with preterm delivery.
    Weiner CP; Grant SS; Williamson RA
    Am J Perinatol; 1991 Jul; 8(4):263-8. PubMed ID: 1720619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Twin pregnancies in the second trimester in women in an alpha-fetoprotein screening program: sonographic evaluation and outcome.
    Pretorius DH; Budorick NE; Scioscia AL; Krabbe JK; Ko S; Myhre CM
    AJR Am J Roentgenol; 1993 Nov; 161(5):1007-13. PubMed ID: 7506005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of MSAFP screening on genetic services, 1984-1986.
    Greenberg F
    Am J Med Genet; 1988 Sep; 31(1):223-30. PubMed ID: 2464932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Maternal serum alpha-fetoprotein as a screening test for fetal Down syndrome].
    Bessho T; Kanazawa R; Shiotani T; Mitsuo M; Koyama K
    Nihon Sanka Fujinka Gakkai Zasshi; 1995 Mar; 47(3):237-43. PubMed ID: 7535328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient acceptance of prenatal alpha-fetoprotein screening: a preliminary study.
    Sikkink J
    Fam Pract Res J; 1990; 10(2):123-31. PubMed ID: 1705075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early pregnancy screening for neural tube defects in Israel.
    Legum C; Shomrat R; Yedwab G; Jaffa AJ; Rudick A
    Isr J Med Sci; 1986; 22(3-4):210-4. PubMed ID: 2427475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Placental mosaicism is associated with unexplained second-trimester elevation of MShCG levels, but not with elevation of MSAFP levels.
    Morssink LP; Sikkema-Raddatz B; Beekhuis JR; De Wolf BT; Mantingh A
    Prenat Diagn; 1996 Sep; 16(9):845-51. PubMed ID: 8905899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated maternal serum alpha-fetoprotein with low unconjugated estriol and the risk for lethal perinatal outcome.
    Benn PA; Craffey A; Horne D; Ramsdell L; Rodis JF
    J Matern Fetal Med; 2000; 9(3):165-9. PubMed ID: 10914624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unexplained elevations of maternal serum alpha-fetoprotein in women with antiphospholipid antibodies: a harbinger of fetal death.
    Silver RM; Draper ML; Byrne JL; Ashwood EA; Lyon JL; Branch DW
    Obstet Gynecol; 1994 Jan; 83(1):150-5. PubMed ID: 7505912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.